Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Globalagliatin Hydrochloride After Multiple Ascending Doses in Patients With Type 2 Diabetes Mellitus

NCT03414892 is registered in ClinicalTrials.gov with Yabao Pharmaceutical Group as lead sponsor.

NCT NCT03414892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03414892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Globalagliatin Hydrochloride After Multiple Ascending Doses in Patients With Type 2 Diabetes Mellitus
Lead sponsor
Yabao Pharmaceutical Group
Phase
Phase 1
Overall status
Completed
Start date
January 3, 2018
Completion date
December 1, 2019
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperglycaemia (diabetic), type 2 diabetes mellitus